[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019005491A - Anticuerpo que enlaza especificamente a cd66c y uso del mismo. - Google Patents

Anticuerpo que enlaza especificamente a cd66c y uso del mismo.

Info

Publication number
MX2019005491A
MX2019005491A MX2019005491A MX2019005491A MX2019005491A MX 2019005491 A MX2019005491 A MX 2019005491A MX 2019005491 A MX2019005491 A MX 2019005491A MX 2019005491 A MX2019005491 A MX 2019005491A MX 2019005491 A MX2019005491 A MX 2019005491A
Authority
MX
Mexico
Prior art keywords
cd66c
antibody
antibody binding
binding specifically
antigen
Prior art date
Application number
MX2019005491A
Other languages
English (en)
Inventor
Pyo Hong Kwon
Yoon Sangsoon
Kim Soseul
Yong Ji Gil
Hoon Lim Young
Original Assignee
Dinona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinona filed Critical Dinona
Publication of MX2019005491A publication Critical patent/MX2019005491A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona a un anticuerpo anti-CD66c y su uso para tratar cáncer, y más particularmente, es posible inducir la activación de célula T o la respuesta inmune humoral utilizando un anticuerpo que reconoce específicamente CD66c. Una molécula de ácido nucleico que codifica el anticuerpo o fragmento de enlace del antígeno del mismo, un vector que comprende la molécula de ácido nucleico, una célula hospedera y el anticuerpo o fragmento de enlace de antígeno del mismo se utiliza para el alivio, prevención, tratamiento o diagnosis de la enfermedad relacionada con CD66c.
MX2019005491A 2016-11-14 2017-11-14 Anticuerpo que enlaza especificamente a cd66c y uso del mismo. MX2019005491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160151359 2016-11-14
PCT/KR2017/012891 WO2018088877A2 (ko) 2016-11-14 2017-11-14 CD66c에 특이적으로 결합하는 항체 및 그의 용도

Publications (1)

Publication Number Publication Date
MX2019005491A true MX2019005491A (es) 2019-08-12

Family

ID=62110206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005491A MX2019005491A (es) 2016-11-14 2017-11-14 Anticuerpo que enlaza especificamente a cd66c y uso del mismo.

Country Status (13)

Country Link
US (1) US11220543B2 (es)
EP (1) EP3560957A4 (es)
JP (2) JP2019535319A (es)
KR (1) KR102019032B1 (es)
CN (1) CN110382533B (es)
AU (1) AU2017358359B2 (es)
BR (1) BR112019009771A2 (es)
CA (1) CA3043691C (es)
IL (1) IL266516B (es)
MX (1) MX2019005491A (es)
PH (1) PH12019501050A1 (es)
SG (1) SG11201903800XA (es)
WO (1) WO2018088877A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628688A1 (en) 2015-03-23 2020-04-01 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof
WO2019221574A1 (ko) * 2018-05-14 2019-11-21 다이노나(주) 골수유래억제세포 관련 질환의 예방 및 치료 용도
KR102373502B1 (ko) * 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
JP2022513036A (ja) * 2018-11-14 2022-02-07 バイエル アクチェンゲゼルシャフト がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ
KR102027248B1 (ko) * 2018-12-14 2019-10-01 건양대학교 산학협력단 유방암 줄기세포 검출용 바이오마커 및 이의 용도
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102456A1 (en) 2004-03-27 2005-11-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
US8883162B2 (en) * 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US8748356B2 (en) * 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
KR101214177B1 (ko) * 2010-02-26 2012-12-21 다이노나(주) ＣＤ66ｃ의 폐선암 특이적 에피토프 및 이를 인식하는 항체
US8404812B2 (en) 2010-02-26 2013-03-26 Dinona Inc. Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same
EA029419B1 (ru) * 2010-11-19 2018-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Нейтрализующие антитела против ccl20
EA037351B8 (ru) * 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
RU2697522C1 (ru) * 2013-11-25 2019-08-15 СиСиЭйЭм БАЙОТЕРАПЬЮТИКС ЛТД. Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака
KR101710936B1 (ko) 2014-09-12 2017-02-28 전영권 태양전지 및 그 제조방법
EP3628688A1 (en) * 2015-03-23 2020-04-01 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
WO2017209318A1 (ko) 2016-05-30 2017-12-07 다이노나(주) 탄산탈수소화 효소에 결합하는 항체 및 이의 용도

Also Published As

Publication number Publication date
CN110382533B (zh) 2023-09-22
PH12019501050A1 (en) 2019-12-11
JP2021177770A (ja) 2021-11-18
WO2018088877A9 (ko) 2018-11-08
BR112019009771A2 (pt) 2019-09-17
IL266516A (en) 2019-08-29
WO2018088877A3 (ko) 2018-10-04
CA3043691A1 (en) 2018-05-17
CA3043691C (en) 2022-11-29
KR102019032B1 (ko) 2019-09-06
KR20180054492A (ko) 2018-05-24
JP7450585B2 (ja) 2024-03-15
IL266516B (en) 2021-12-01
US20190263905A1 (en) 2019-08-29
JP2019535319A (ja) 2019-12-12
AU2017358359B2 (en) 2021-04-01
EP3560957A2 (en) 2019-10-30
WO2018088877A2 (ko) 2018-05-17
SG11201903800XA (en) 2019-05-30
US11220543B2 (en) 2022-01-11
AU2017358359A1 (en) 2019-05-30
CN110382533A (zh) 2019-10-25
EP3560957A4 (en) 2020-10-21

Similar Documents

Publication Publication Date Title
PH12019501050A1 (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
PH12017500890A1 (en) Antibody drug conjugates
MX2022002504A (es) Anticuerpos para cd40.
GEP20217220B (en) Pd1 and/or lag3 binders
NZ738008A (en) Tigit-binding agents and uses thereof
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
PH12016501384B1 (en) Human antibodies to pd-l1
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
MY176475A (en) Human antibodies to pd-1
MX2018003470A (es) Nuevo anticuerpo anti-mesotelina y composicion que comprende el mismo.
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
WO2014118236A3 (en) High avidity binding molecules recognizing mage-a1
BR112018068678A2 (pt) anticorpos anti-mica
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
MX2019005492A (es) Anticuerpo que enlaza a anhidrasa carbonica y uso del mismo.
IN2014DN09717A (es)
MX2018001964A (es) Polipeptidos mrka, anticuerpos y usos de los mismos.
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения